Clinical trials are time consuming, expensive, and often burdensome on patients. Clinical
trials can fail for many reasons. This survey reviews many of these reasons and offers …

Antibody-drug conjugates (ADCs) represent a new class of cancer therapeutics. Their
design involves a tumor-specific antibody, a linker and a cytotoxic payload. They were …

As the popularity and diversity of social media platforms increases so does their utility for
health research. Using social media for recruitment into clinical studies and/or delivering …

Drug repositioning, the process of discovering, validating, and marketing previously
approved drugs for new indications, is of growing interest to academia and industry due to …

Simple Summary Antibody-drug conjugates (ADC) are a rapidly expanding class of anti-
cancer drugs, with twelve agents in current clinical use. Despite recent successes, many …

The practice of offering payment to individuals in exchange for their participation in clinical
research is widespread and longstanding. Nevertheless, such payment remains the source …

10-Year Update on ClinicalTrials. gov A decade after ClinicalTrials. gov launched a
database for reporting results of clinical trials, the database includes results of approximately …

BACKGROUND: Trial discontinuation and nonpublication represent potential waste in
research resources and lead to compromises in medical evidence. Pediatric trials may be …

The majority of cardiovascular randomized controlled trials (RCTs) test interventions in
selected patient populations under explicitly protocol-defined settings. Although these …

Background The demand for clinical trial participants is today one of the highest it has ever
been and continues to increase. At the same time, subject recruitment continues to be …